Affimed NV (AFMD) unveiled how its immunological therapy has helped treat Hodgkin’s lymphoma. Even though the news only concerns four patients, it was well-received by investors. On April 13, AFMD shares were worth $ 9.89. The stock had gained more than 24% during the week. The stock also gained 34.92% last month, 57.48% in 3 months, and 167.30% in 6 months. AFMD was found to have an 8.62% volatility during the week and 7.44% volatility during the month.
There have only been four patient samples released, but even this data impressed investors. The Affimed study analyzed the action of the cellular drug AFM13 on patients with Hodgkin’s lymphoma. AFM13, which attracts natural killer cells to tumour cells, was administered to all four patients and administered immune cells called natural killer (NK) cells. Two patients responded thoroughly, and two others responded partially.
Before being injected with NK cells and AFM13, all of the patients who participated in the study had already attempted 4 to 14 therapy lines unsuccessfully. One patient who responded completely received one cycle of the lower dose, while three patients received two cycles of the lowest dose. At the lower dose level, the patient had his second complete response after the second cycle.
Therefore, a higher amount of the medication or an additional dose may help the patient. It has been found that the safety profile of the therapy was good. Remarkably, there have been no reports of cytokine release syndromes, neurotoxic syndromes, and cases of graft versus host disease as some of the significant side effects of cell-based immunotherapies.
Affimed NV (AFMD) intends to continue researching the treatment by attracting three more clients for it only, and only after that will they proceed to the next and final level of the treatment. Furthermore, Affimed is conducting clinical trials of AFM13 for therapeutic effects in various tumour types, including Hodgkin’s lymphoma, which can be used alone or in combination with various treatments.